Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 6, 2003. The report details a share re-purchase transaction and updates regarding director interests in company shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. Specific transaction data includes:
- Share Re-purchase: 854,000 Ordinary 25 pence shares purchased for cancellation on August 4, 2003.
- Re-purchase Price: 1,168.27 pence per share.
- US Retirement Savings Plan: The fund's holding of Ordinary Share ADRs increased from 18,991,879 to 19,070,791 as of August 1, 2003, at an average price of $37.40.
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 854,000 shares. Additionally, the US Retirement Savings Plan saw an increase in ADR holdings due to fund movements.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The share re-purchase was executed in accordance with authority granted by shareholders at the Annual General Meeting on May 19, 2003.
Investor Verification Points
- Verify the total number of shares repurchased and cancelled against the company's authorized share capital limits.
- Confirm the impact of the share cancellation on earnings per share (EPS) in subsequent reports.
- Review the full details of the US Retirement Savings Plan to understand the extent of director Dr. J P Garnier's potential interest.